Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar mgm4 (< 20) Submitted: 8/30/2011 2:55:16 PM : Outperform Start Price: $1.91 NVAX Score: -41.96

Flu season...media...paranoia

Featured Broker Partners


Advertisement